ESMO2018 演題レポート Munich, Germany 19 Oct - 23 Oct 2018

2018年10月19日~23日にドイツ・ミュンヘンで開催された 2018年 欧州臨床腫瘍学会学術集会(ESMO 2018 Congress)より、大腸癌や胃癌などの消化器癌の注目演題のレポートをお届けします。演題レポートの冒頭には、臨床研究の第一線で活躍する監修ドクターのコメントを掲載します。

Live Short Cuts

演題レポート

Proffered Paper Session

#LBA18
大腸癌

Durable clinical benefit with nivolumab plus low-dose ipilimumab as first-line in microsatellite instability –high/mismatch repair deficient metastatic colorectal cancer.

Heinz-Josef J. Lenz, et al.

#LBA19
大腸癌

Fluoropyrimidine (FP) + bevacizumab (BEV) + atezolizumab vs FP/BEV in BRAFwt metastatic colorectal cancer (mCRC): Findings from cohort 2 of MODUL – a multicentre, randomized trial of biomarker-driven maintenance treatment following first-line induction therapy.

Axel Grothey, et al.

#LBA20
大腸癌

TRIBE2: a phase III, randomized strategy study by GONO in the 1st- and 2nd-line treatment of unresectable metastatic colorectal cancer (mCRC) patients (pts).

Chiara Cremolini, et al.

#LBA25
胃癌

TAGS: a phase 3, randomised, double-blind study of trifluridine/tipiracil (TAS-102) versus placebo in patients with refractory metastatic gastric cancer.

Hendrik-Tobias Arkenau, et al.

#LBA26
肝細胞癌

Updated safety and clinical activity results from a Phase Ib study of atezolizumab + bevacizumab in hepatocellular carcinoma (HCC).

Michael J. Pishvaian, et al.

#LBA27
肝細胞癌

A randomized multicentered phase 2 study to evaluate SHR-1210 (PD-1 antibody) in subjects with advanced hepatocellular carcinoma (HCC) who failed or intolerable to prior systemic treatment.

Shu K. Qin, et al.

#50O
がん全般

Plasma cell-free DNA (cfDNA) assays for early multi-cancer detection: the circulating cell-free genome atlas (CCGA) study.

Minetta C. Liu, et al.

#615O
胆道癌

Randomized phase III study of gemcitabine, cisplatin plus S-1 (GCS) versus gemcitabine, cisplatin (GC) for advanced biliary tract cancer (KHBO1401-MITSUBA).

Daisuke Sakai, et al.

Poster Discussion Session

#LBA28
胆道癌

Updated results from a phase II study of infigratinib (BGJ398), a selective pan-FGFR kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma containing FGFR2 fusions.

Milind Jovle, et al.

#453PD
大腸癌

Efficacy and quality of life in VOLFI trial: mFOLFOXIRI + Panitumumab versus FOLFOXIRI as first-line treatment in patients with RAS wild-type metastatic colorectal cancer (mCRC): a randomized phase II trial of the AIO (AIO-KRK-0109).

Michael Geissler, et al.

#454PD
大腸癌

Influence of treatment with prior bevacizumab: A combined analysis of individual patient data from ASPECCT and WJOG6510G trial which compared panitumumab versus cetuximab in patients with wild-type KRAS exon2 metastatic colorectal cancer.

Hiroya Taniguchi, et al.

#617PD
胃癌および胃食道接合部癌

A phase 3 study of nivolumab (Nivo) in previously treated advanced gastric or gastric esophageal junction (G/GEJ) cancer (ATTRACTION-2): Two-years update data.

Taroh Sato, et al.

#620PD
食道癌

Enteral nutrition improves nutritional status, treatment tolerance and outcomes in patients with esophageal cancer undergoing concurrent chemoradiotherapy: results of a prospective, randomized, controlled, multicenter trial (NCT02399306).

Tao Li, et al.

Poster Display Session

#467P
大腸癌

Prospective evaluation of regorafenib dose escalation strategy with low starting dose in patients with colorectal cancer.

Toshiki Masuishi, et al.

#563P
大腸癌

Updated results of phase 1 study of trastuzumab deruxtecan (DS-8201a) in HER2-expressing advanced colorectal cancer.

Takayuki Yoshino, et al.

#667P+668P
胃癌

A phase II study of Trastuzumab with S-1 plus Oxaliplatin for HER2-positive advanced gastric cancer (HIGHSOX).

Keisho Chin, et al.

Updated analysis of a phase II study of SOX plus trastuzumab for the patients with HER2 positive advanced or recurrent gastric cancer: KSCC/HGCSG/CCOG/PerSeUS1501B.

Satoshi Yuki, et al.

by European Society for Medical Oncology

by European Society for Medical Oncology

by European Society for Medical Oncology

by European Society for Medical Oncology